AR047890A1 - Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 - Google Patents
Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3Info
- Publication number
- AR047890A1 AR047890A1 ARP050100632A ARP050100632A AR047890A1 AR 047890 A1 AR047890 A1 AR 047890A1 AR P050100632 A ARP050100632 A AR P050100632A AR P050100632 A ARP050100632 A AR P050100632A AR 047890 A1 AR047890 A1 AR 047890A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- alkyl
- alkanoyl
- haloalkyl
- cyano
- Prior art date
Links
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 title 2
- 229960003638 dopamine Drugs 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 5
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 3
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- 125000002861 (C1-C4) alkanoyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004076 pyridyl group Chemical group 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 abstract 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 abstract 1
- 102000004073 Dopamine D3 Receptors Human genes 0.000 abstract 1
- 108090000525 Dopamine D3 Receptors Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 239000000164 antipsychotic agent Substances 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 229910052801 chlorine Inorganic materials 0.000 abstract 1
- 239000000460 chlorine Substances 0.000 abstract 1
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 206010013663 drug dependence Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Anesthesiology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0403990A GB0403990D0 (en) | 2004-02-23 | 2004-02-23 | Compounds |
| GB0404083A GB0404083D0 (en) | 2004-02-24 | 2004-02-24 | Compounds |
| GB0417120A GB0417120D0 (en) | 2004-07-30 | 2004-07-30 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR047890A1 true AR047890A1 (es) | 2006-03-01 |
Family
ID=34890800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP050100632A AR047890A1 (es) | 2004-02-23 | 2005-02-21 | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 |
Country Status (25)
| Country | Link |
|---|---|
| US (3) | US7855298B2 (https=) |
| EP (3) | EP2070922B1 (https=) |
| JP (1) | JP4960217B2 (https=) |
| KR (1) | KR101143718B1 (https=) |
| CN (1) | CN1946714B (https=) |
| AR (1) | AR047890A1 (https=) |
| AT (3) | ATE451364T1 (https=) |
| AU (2) | AU2005215918C1 (https=) |
| BR (1) | BRPI0507945A (https=) |
| CA (1) | CA2557115C (https=) |
| CY (3) | CY1109854T1 (https=) |
| DE (1) | DE602005018190D1 (https=) |
| DK (3) | DK2060570T3 (https=) |
| ES (2) | ES2380990T3 (https=) |
| HR (3) | HRP20100114T1 (https=) |
| IL (1) | IL177184A0 (https=) |
| MA (1) | MA28438B1 (https=) |
| NO (1) | NO20064309L (https=) |
| PE (1) | PE20051173A1 (https=) |
| PL (3) | PL2060570T3 (https=) |
| PT (3) | PT2070922E (https=) |
| RU (1) | RU2434011C2 (https=) |
| SI (3) | SI1745040T1 (https=) |
| TW (1) | TW200538113A (https=) |
| WO (1) | WO2005080382A1 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20051173A1 (es) * | 2004-02-23 | 2006-02-14 | Glaxo Group Ltd | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 |
| US20070043100A1 (en) | 2005-08-16 | 2007-02-22 | Hagen Eric J | Novel polymorphs of azabicyclohexane |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| GB0512099D0 (en) * | 2005-06-14 | 2005-07-20 | Glaxo Group Ltd | Compounds |
| WO2006133945A1 (en) | 2005-06-14 | 2006-12-21 | Glaxo Group Limited | Novel compounds |
| WO2007006117A1 (en) * | 2005-07-13 | 2007-01-18 | Nicogen Inc. | Novel cyp2a6 inhibitors |
| NZ592836A (en) * | 2005-07-27 | 2013-01-25 | Dov Pharmaceutical Inc | Novel 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders |
| GB0517191D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| WO2007022933A1 (en) * | 2005-08-22 | 2007-03-01 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine d3 receptors |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| AR060237A1 (es) * | 2006-04-03 | 2008-06-04 | Glaxo Group Ltd | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. |
| GB0703387D0 (en) * | 2007-02-21 | 2007-03-28 | Glaxo Group Ltd | Novel compounds |
| GB0607899D0 (en) * | 2006-04-03 | 2006-05-31 | Glaxo Group Ltd | Process for preparing heterocyclic derivatives |
| US8222266B2 (en) * | 2006-04-03 | 2012-07-17 | Glaxo Group Limited | Azabicyclo [3.1.0] hexyl derivatives as modulators of dopamine D3 receptors |
| US8163927B2 (en) * | 2006-04-03 | 2012-04-24 | Glaxo Group Limited | Azabicyclo [3.1.0] hexane derivatives as modulators of dopamine D3 receptors |
| GB0608452D0 (en) * | 2006-04-27 | 2006-06-07 | Glaxo Group Ltd | Novel compounds |
| US20080045725A1 (en) | 2006-04-28 | 2008-02-21 | Murry Jerry A | Process For The Synthesis of (+) And (-)-1-(3,4-Dichlorophenyl)-3-Azabicyclo[3.1.0]Hexane |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
| US8138377B2 (en) | 2006-11-07 | 2012-03-20 | Dov Pharmaceutical, Inc. | Arylbicyclo[3.1.0]hexylamines and methods and compositions for their preparation and use |
| US20090069374A1 (en) * | 2007-06-06 | 2009-03-12 | Phil Skolnick | Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments |
| US9133159B2 (en) | 2007-06-06 | 2015-09-15 | Neurovance, Inc. | 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments |
| GB0719235D0 (en) * | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| GB0719234D0 (en) * | 2007-10-02 | 2007-11-14 | Glaxo Group Ltd | Novel compounds |
| CN102816106A (zh) | 2008-06-24 | 2012-12-12 | 默沙东公司 | 用于制备基本上立体异构纯的稠合二环脯氨酸化合物的生物催化方法 |
| US8536185B2 (en) | 2008-09-22 | 2013-09-17 | Cayman Chemical Company, Incorporated | Multiheteroaryl compounds as inhibitors of H-PGDS and their use for treating prostaglandin D2 mediated diseases |
| BR112012000657A2 (pt) | 2009-06-26 | 2016-11-16 | Panacea Biotec Ltd | novos azabicilohexanos |
| US20140206740A1 (en) | 2011-07-30 | 2014-07-24 | Neurovance, Inc. | Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters |
| US20160279098A1 (en) * | 2013-11-11 | 2016-09-29 | Euthymics Bioscience, Inc. | Novel methods |
| HK1250029A1 (zh) | 2015-08-05 | 2018-11-23 | Indivior Uk Limited | 具有双环结构的多巴胺d3受体拮抗剂 |
| JP7250405B2 (ja) | 2018-01-26 | 2023-04-03 | 塩野義製薬株式会社 | ドーパミンｄ３受容体拮抗作用を有する環式化合物 |
| CN116113627B (zh) | 2020-06-22 | 2025-06-03 | 科赛普特治疗公司 | 季吲哚糖皮质激素受体拮抗剂 |
| US12115154B2 (en) | 2020-12-16 | 2024-10-15 | Srx Cardio, Llc | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) |
| IL313667A (en) | 2021-12-21 | 2024-08-01 | Corcept Therapeutics Inc | Glucocorticoid receptor antagonists INDAZOL CYCLES |
| CA3243549A1 (en) | 2021-12-21 | 2023-06-29 | Corcept Therapeutics Incorporated | INDAZOLE PIPERAZINE-BASED GLUCOCORTICOID RECEPTOR ANTAGONISTS |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI274750B (en) * | 1999-01-12 | 2007-03-01 | Abbott Gmbh & Co Kg | Triazole compounds showing high affinity to dopamine D3 receptor and pharmaceutical composition comprising the same |
| GB0015562D0 (en) * | 2000-06-23 | 2000-08-16 | Pfizer Ltd | Heterocycles |
| JP4272423B2 (ja) | 2000-11-14 | 2009-06-03 | スミスクライン ビーチャム ピー エル シー | ドーパミンｄ３受容体のモジュレーターとして有用なテトラヒドロベンズアゼピン誘導体（抗精神病剤） |
| US6569887B2 (en) * | 2001-08-24 | 2003-05-27 | Dov Pharmaceuticals Inc. | (−)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake |
| EP1440059B1 (en) | 2001-10-22 | 2008-04-16 | Pfizer Products Inc. | 3-azabicyclo(3.1.0)hexane derivatives as opioid receptor antagonists |
| IL166510A0 (en) * | 2002-08-09 | 2006-01-15 | Nps Pharma Inc | 1,2,4"oxadiazole as modulators of metabotropic glutamate receptor-5 |
| PE20051173A1 (es) * | 2004-02-23 | 2006-02-14 | Glaxo Group Ltd | Compuestos azabiciclico (3.1.0) hexanos como moduladores de receptores de dopamina d3 |
| GB0507601D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507602D0 (en) * | 2005-04-14 | 2005-05-18 | Glaxo Group Ltd | Compounds |
| GB0507680D0 (en) * | 2005-04-15 | 2005-05-25 | Glaxo Group Ltd | Compounds |
| WO2006133945A1 (en) * | 2005-06-14 | 2006-12-21 | Glaxo Group Limited | Novel compounds |
| GB0517175D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517191D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| GB0517193D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Novel use |
| WO2007022933A1 (en) * | 2005-08-22 | 2007-03-01 | Glaxo Group Limited | Triazole derivatives as modulators of dopamine d3 receptors |
| GB0517187D0 (en) * | 2005-08-22 | 2005-09-28 | Glaxo Group Ltd | Compounds |
| AR060237A1 (es) * | 2006-04-03 | 2008-06-04 | Glaxo Group Ltd | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. |
| GB0616574D0 (en) * | 2006-08-21 | 2006-09-27 | Glaxo Group Ltd | Compounds |
-
2005
- 2005-02-21 PE PE2005000205A patent/PE20051173A1/es not_active Application Discontinuation
- 2005-02-21 AT AT05707610T patent/ATE451364T1/de active
- 2005-02-21 SI SI200530923T patent/SI1745040T1/sl unknown
- 2005-02-21 TW TW094105108A patent/TW200538113A/zh unknown
- 2005-02-21 AT AT08169935T patent/ATE542816T1/de active
- 2005-02-21 SI SI200531398T patent/SI2070922T1/sl unknown
- 2005-02-21 US US10/598,200 patent/US7855298B2/en not_active Expired - Fee Related
- 2005-02-21 PT PT08169934T patent/PT2070922E/pt unknown
- 2005-02-21 ES ES08169935T patent/ES2380990T3/es not_active Expired - Lifetime
- 2005-02-21 PL PL08169935T patent/PL2060570T3/pl unknown
- 2005-02-21 WO PCT/EP2005/001940 patent/WO2005080382A1/en not_active Ceased
- 2005-02-21 EP EP08169934A patent/EP2070922B1/en not_active Expired - Lifetime
- 2005-02-21 DK DK08169935.7T patent/DK2060570T3/da active
- 2005-02-21 PT PT05707610T patent/PT1745040E/pt unknown
- 2005-02-21 JP JP2007500152A patent/JP4960217B2/ja not_active Expired - Fee Related
- 2005-02-21 SI SI200531503T patent/SI2060570T1/sl unknown
- 2005-02-21 RU RU2006133909/04A patent/RU2434011C2/ru not_active IP Right Cessation
- 2005-02-21 AR ARP050100632A patent/AR047890A1/es not_active Application Discontinuation
- 2005-02-21 ES ES05707610T patent/ES2337590T3/es not_active Expired - Lifetime
- 2005-02-21 KR KR1020067016833A patent/KR101143718B1/ko not_active Expired - Fee Related
- 2005-02-21 EP EP08169935A patent/EP2060570B1/en not_active Expired - Lifetime
- 2005-02-21 CA CA2557115A patent/CA2557115C/en not_active Expired - Fee Related
- 2005-02-21 DE DE602005018190T patent/DE602005018190D1/de not_active Expired - Lifetime
- 2005-02-21 BR BRPI0507945-4A patent/BRPI0507945A/pt active Search and Examination
- 2005-02-21 AT AT08169934T patent/ATE520686T1/de active
- 2005-02-21 PT PT08169935T patent/PT2060570E/pt unknown
- 2005-02-21 PL PL08169934T patent/PL2070922T3/pl unknown
- 2005-02-21 DK DK05707610.1T patent/DK1745040T3/da active
- 2005-02-21 EP EP05707610A patent/EP1745040B9/en not_active Expired - Lifetime
- 2005-02-21 DK DK08169934.0T patent/DK2070922T3/da active
- 2005-02-21 HR HR20100114T patent/HRP20100114T1/hr unknown
- 2005-02-21 AU AU2005215918A patent/AU2005215918C1/en not_active Ceased
- 2005-02-21 PL PL05707610T patent/PL1745040T3/pl unknown
- 2005-02-21 CN CN2005800126155A patent/CN1946714B/zh not_active Expired - Fee Related
-
2006
- 2006-07-31 IL IL177184A patent/IL177184A0/en unknown
- 2006-08-22 MA MA29286A patent/MA28438B1/fr unknown
- 2006-09-22 NO NO20064309A patent/NO20064309L/no not_active Application Discontinuation
-
2009
- 2009-09-01 AU AU2009212887A patent/AU2009212887A1/en not_active Abandoned
- 2009-12-16 US US12/639,129 patent/US8263782B2/en not_active Expired - Fee Related
- 2009-12-16 US US12/639,282 patent/US8283474B2/en not_active Expired - Fee Related
-
2010
- 2010-03-01 CY CY20101100197T patent/CY1109854T1/el unknown
-
2011
- 2011-10-26 HR HR20110781T patent/HRP20110781T1/hr unknown
- 2011-11-07 CY CY20111101073T patent/CY1112011T1/el unknown
-
2012
- 2012-03-29 HR HR20120281T patent/HRP20120281T1/hr unknown
- 2012-04-11 CY CY20121100356T patent/CY1113029T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR047890A1 (es) | Derivados de azabiciclo[3.1.0]hexano como moduladores de los receptores de dopamina d3 | |
| AR060237A1 (es) | Compuesto de 3-azabiciclo[3.1.0]hexano como moduladores del receptor de dopamina d3, su uso para la preparacion de un medicamento para el tratamiento de afecciones psicoticas y composicion farmaceutica que lo comprende. | |
| AR062360A1 (es) | Derivados heterociclicos que modulan la actividad de la estearoil-coa-desaturasa | |
| AR127309A2 (es) | Derivados de piridazinona | |
| MY144048A (en) | Chemical compound | |
| AR074596A1 (es) | Derivados de (3-oxo) piridazin-4-ilurea | |
| AR062737A1 (es) | Composicion farmaceutica que comprende un compuesto derivado de aril-azabiciclo, compuesto correspondiente y su uso para la preparacion de un medicamento | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| AR079205A1 (es) | Morfolinotiazoles como moduladores alostericos positivos alfa 7 | |
| AR085615A1 (es) | Derivados de fluoropiridinona utiles como agentes antibacterianos y composiciones farmaceuticas que los contienen | |
| AR067757A1 (es) | Derivados de imidazo[4,5-c]piridin-2-ona, composiciones farmaceuticas que los contienen, procedimiento para su preparacion y uso de los mismos como agentes antivirales. | |
| AR035774A1 (es) | Derivados benzimidazol y piridilimidazol, un procedimiento para su preparacion, composiciones farmaceuticas y paquetes que los comprenden, el uso de dichos compuestos solos o en combinacion para la manufactura de medicamentos como ligandos para gabaa, y metodo de tratamiento | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR061134A1 (es) | Derivados de tioxantina | |
| ATE487715T1 (de) | Triazolderivate als modulatoren von dopamin-d3- rezeptoren | |
| AR080467A1 (es) | Derivados tetrazolicos moduladores selectivos de receptores cb2, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del dolor y otras enfermedades | |
| HRP20080052T3 (hr) | Derivati tropana supstituirani imidazopiridinom santagonističkim djelovanjem na ccr5 receptor za liječenje hiv-a i upala | |
| AR075367A1 (es) | Inhibidores de glucosilceramida sintasa | |
| AR064831A1 (es) | Derivados de espiropiperidina-glicinamida | |
| AR116022A1 (es) | Compuestos heteroaromáticos como inhibidores de vanina | |
| ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| PE20201068A1 (es) | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos | |
| PE20190980A1 (es) | Compuestos terapeuticos y metodos para utilizarlos | |
| BRPI0809983A2 (pt) | Quinolinas e seu uso terapêutico |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |